GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical and consumer health-related products worldwide. The company operates in two segments, Pharmaceuticals and Consumer Healthcare. The Pharmaceutical segment offers prescription pharmaceuticals and vaccines. Its primary pharmaceutical products include medicines in nine therapeutic areas, including central nervous system, respiratory, anti-virals, anti-bacterials, vaccines, oncology and emesis, metabolic, cardiovascular, and urogenital. The Consumer Healthcare segment provides various over-the-counter medicines, oral care, and nutritional healthcare products.

One of the top five pharmaceutical firms in the world, GSK’s top sellers include asthma medication Advair. Other bestsellers include anti-depressants Paxil and Wellbutrin, migraine therapy Imitrex, antibiotic Augmentin, and erectile dysfunction drug Lavitra. The company’s consumer products include Tums for sour stomachs and cold sore fighter Abreva. For smokers GSK offers several cessation products like Commit, NicoDerm, and Nicorette.

Glaxosmithkline plc
980 Great West Road
Brentford, TW8 9GS
Phone: 44 20 8047 5000
Fax: 44 20 8047 7807

£1.5bn Tax Bill

Drug giant plans court challenge against tax authorities in long-running dispute over profit allocation, writes Rosie Murray-West

Glaxo Smithkline, the drug giant, yesterday revealed that it had received a £1.5billion bill from the US tax authorities and estimated it could also owe £1.4 billion in interest unless it wins a case against them

Glaxo’s CEO to scoop 5.7 mln stg a year

LONDON, Dec 14 (Reuters) – Jean-Pierre Garnier, chief executive of GlaxoSmithKline Plc , will earn up to 5.7 million pounds ($9

FDA tells Glaxo to pull misleading Flonase ads

U.S. regulators ordered GlaxoSmithKline Plc to pull radio and print advertisements for its Flonase prescription nasal allergy spray that the Food and Drug Administration deemed misleading

Ordered to pull misleading adverts

The US government has ordered a drug giant to quit running a series of radio and newspaper ads that call the allergy spray Flonase a cost-effective alternative to pricey allergy pills.

The ad campaign urged allergy sufferers to ask their doctor about Flonase, a nasal spray, instead of antihistamine pills like Allegra and Zyrtec. Flonase maker GlaxoSmithKline began the ads shortly after insurance companies raised prices for the pills this spring